There is little time left for Repligen Corporation (RGEN) to reach its 1-year target estimate. How soon will it surpass it?

The stock of Repligen Corporation (NASDAQ:RGEN) last traded at $154.26, down -1.96% from the previous session.

Data from the available sources indicates that Repligen Corporation (NASDAQ:RGEN) is covered by 12 analysts. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $270.00 and a low of $180.00, we find $230.00. Given the previous closing price of $157.34, this indicates a potential upside of 46.18 percent. RGEN stock price is now -11.97% away from the 50-day moving average and -15.89% away from the 200-day moving average. The market capitalization of the company currently stands at $8.74B.

In total, 3 analysts have assigned it a hold rating, and 9 have given it a buy rating. Brokers who have rated the stock have averaged $225.55 as their price target over the next twelve months.

With the price target of $180, Deutsche Bank recently initiated with Hold rating for Repligen Corporation (NASDAQ: RGEN). On December 07, 2022, RBC Capital Mkts recently initiated its ‘Sector Perform’ rating on the stock quoting a target price of $190, while ‘UBS’ rates the stock as ‘Buy’.

In other news, Hunt Anthony, Chief Executive Officer sold 25,000 shares of the company’s stock on Nov 11. The stock was sold for $5,000,000 at an average price of $200.00. Upon completion of the transaction, the Chief Executive Officer now directly owns 178,265 shares in the company, valued at $27.5 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 09, Director DAWES KAREN A sold 775 shares of the business’s stock. A total of $176,057 was realized by selling the stock at an average price of $227.17. This leaves the insider owning 76,401 shares of the company worth $11.79 million. Insiders disposed of 151,746 shares of company stock worth roughly $23.41 million over the past 1 year. A total of 0.60% of the company’s stock is owned by insiders.

There have been several recent changes in the stakes of large investors in RGEN stock. A new stake in Repligen Corporation shares was purchased by SANDS CAPITAL MANAGEMENT, LLC during the first quarter worth $252,826,000. PENDAL GROUP LTD invested $68,933,000 in shares of RGEN during the first quarter. In the first quarter, CHAMPLAIN INVESTMENT PARTNERS, LLC acquired a new stake in Repligen Corporation valued at approximately $33,742,000. MASSACHUSETTS FINANCIAL SERVICES CO /MA/ acquired a new stake in RGEN for approximately $30,011,000. ZEVENBERGEN CAPITAL INVESTMENTS LLC purchased a new stake in RGEN valued at around $16,696,000 in the second quarter. In total, there are 567 active investors with 93.40% ownership of the company’s stock.

With an opening price of $156.76 on Friday morning, Repligen Corporation (NASDAQ: RGEN) set off the trading day. During the past 12 months, Repligen Corporation has had a low of $137.21 and a high of $262.26. As of last week, the company has a debt-to-equity ratio of 0.15, a current ratio of 2.30, and a quick ratio of 1.70. The fifty day moving average price for RGEN is $174.78 and a two-hundred day moving average price translates $183.25 for the stock.

The latest earnings results from Repligen Corporation (NASDAQ: RGEN) was released for Jun, 2022. According to the Medical Instruments & Supplies Company, earnings per share came in at $0.91, beating analysts’ expectations of $0.72 by 0.19. This compares to $0.58 EPS in the same period last year. The net profit margin was 20.80% and return on equity was 9.30% for RGEN. The company reported revenue of $200.74 million for the quarter, compared to $178.22 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 12.64 percent. For the current quarter, analysts expect RGEN to generate $191.5M in revenue.

Repligen Corporation(RGEN) Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.